NCT02320409已完成1 期
A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects
Hutchison Medipharma Limited1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The following PK parameters will be derived from the plasma concentration-time profile of Sufatinib following administration
研究概览
简要总结
The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 250 mg Sulfatinib and its metabolites in healthy subjects.
详细描述
The purpose of this study is to evaluate to determine the effect of food on the PK( pharmacokinetics) of a single dose of 250 mg Sulfatinib and its metabolites in healthy subjects and to assess the safety and tolerability of single doses of 250mg in healthy subjects.This study will be an open-label, randomized, two-period, crossover PK food effect study of Sulfatinib administered orally at 250 mg. Subjects will be screened for eligibility up to 14 days prior to entry into the study,there will be 2 treatments,2 weeks follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males , between 18 and 55 years of age, inclusive.
- •Body mass index (BMI) within the range of 20 to 30 kg/m2, inclusive.
- •In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs.
- •Adequate hepatic, renal, heart, and hematologic functions
- •Male subjects who are either sterile or agree to use and get the agreement of their sexual partners to use , during the period from informed consent until 90 days following Study Completion, 1 of the following approved methods of contraception: condom, use by female sexual partner of an intrauterine device, contraceptive sponge, diaphragm, or use of a cervical cap; or an oral, implantable, transdermal, injectable contraceptives or other contraceptive measures.
- •Able to comprehend and willing to sign an informed consent form (ICF).
排除标准
- •disease history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric disorder(as determined by the Investigator).
- •History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
- •serum total bilirubin>34.2 umol/L；
- •serum albumin<35 g/L；
- •GFR < 80 mL/min/1.73m
- •Algorithm: GFR (mL/min/1.73m2) =186 × (SCr)-1.154 × (Age)-0.203, Scr= serum creatinine, mg/dL；
- •Blood pressure greater than 140/
- •History or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant.
- •Smoking more than 10 cigarettes daily without intention to quit smoking during study.
- •History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection that would potentially alter absorption and/or excretion of orally administered drugs as determined by the investigator (appendectomy and/or hernia repair may be allowed).
- •Significant allergy history(eg. drug allergy); acute allergic rhinitis or food allergy within 2 weeks prior to informed consent.
- •Donation of blood or plasma ≥ 500 mL from 30 days prior to informed consent, or of blood or plasma ≥250 mL from 2 weeks prior to informed consent.
- •Receipt of blood products within 2 months prior to informed consent;
- •Poor peripheral venous access.
- •Participants who are positive for hepatitis B surface antigen (HBs antigen) or hepatitis B core antibody , hepatitis C virus (HCV) antibody;
- •Participants who are human immunodeficiency virus (HIV)-positive;
- •Diagnosis of alcoholism or drug addiction within 1 year prior to informed consent.
- •Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 5 half-lives or 28 days, whichever is longer prior to informed consent.
- •Use of any prescription medications or products within 14 days prior to informed consent.
- •Use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic, herbal,) within 7 days prior to informed consent.
- •Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices, or beverages within 72 hours prior to informed consent.
- •Use of known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant derived preparations such as St. John's Wort, etc.) for a period of 60 days prior to first dose;
- •principal investigator, investigator, pharmacist, Clinical Research Coordinator or any personnel related to this study.
- •Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.
研究组 & 干预措施
Sulfatinib ,after general diet
Experimental
First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
干预措施: Sulfatinib (Drug)
Sulfatinib, before general diet
Experimental
First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
干预措施: Sulfatinib (Drug)
结局指标
主要结局
The following PK parameters will be derived from the plasma concentration-time profile of Sufatinib following administration
时间窗: 1-3 days
Area Under Curve (AUC), both from time zero to time with last observation and from time zero to infinity;;Maximum plasma concentration (Cmax);Time to reach the Cmax (Tmax);elimination half-life
次要结局
- AE (adverse event) will be summarized by type and severity(1 day to the 14 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clifutinib Food Effect Study in Healthy SubjectsAcute Myeloid Leukemia in ChildrenNCT05454098Sunshine Lake Pharma Co., Ltd.40
已完成
1 期
A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy ParticipantsHealthyNCT04258189Janssen Research & Development, LLC16
已完成
1 期
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomaNCT01898078Millennium Pharmaceuticals, Inc.26
已完成
1 期
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerNon Small Cell Lung Cancer (NSCLC)Estrogen Receptor Breast CancerBreast CancerLung CancerNCT01594398Syndax Pharmaceuticals14
已完成
1 期
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington DiseaseHuntington's DiseaseNCT01485965Siena Biotech S.p.A.26